Journal
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
Volume 10, Issue 5, Pages 649-658Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/17474124.2016.1139450
Keywords
HBV infection; antiviral therapy; interferon; entecavir; children
Categories
Ask authors/readers for more resources
Chronic hepatitis B (CHB) in children shows a variety of clinical presentations, which influence its natural course and treatment options. This report provides an overview of the ongoing strategies in pediatric CHB management. Interferon- represents the first choice of treatment in children showing HBV replication and hepatic inflammation (immune active CHB), while the recommendation is to monitor inactive/immune-tolerant children (normal transaminases and low/absent viral replication). When circumstances preclude the use of Interferon- and in cases of compensated/decompensated cirrhosis, entecavir for children above 2 years of age or tenofovir for children above 12 years of age are the nucleos(t)ide analogues recommended by the most recent guidelines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available